Glaxo to benefit from likely revision in formulation price - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Feb 9, 2000 - Glaxo to benefit from likely revision in formulation price

Glaxo to benefit from likely revision in formulation price

Feb 9, 2000

The National Pharmaceutical Pricing Authority (NPPA) is likely to revise (upwards) the prices of betamethasone (‘Betnovate’) formulations. The decision, if it materialises, would come into force within six to eight weeks. Glaxo India is a 51% subsidiary of the £ 8 billion Glaxo Plc. UK which has blockbusters like Zantac and Zovirax to its credit. It has two other group companies Burroughs Wellcome India and Biddle Sawyer. The company has almost 60% of its revenues accruing from products, which are under price control and betamethasone formulations account for a fourth of such revenues.

The NPPA was set up in 1997 as the official body to administer the Drug Price Control Order (DPCO). It announces price revisions almost every month. Most of the times the recommendations do affect the multinational pharmaceutical companies since they are the ones which have a relatively higher proportion (anywhere between 45-60%) of the revenues accruing from products under price control.

Glaxo would be among the largest beneficiaries of an upward revision in Betamethasone based formulations since these account for around 15% of its turnover. The companies Betnovate-C and Betnovate-N brands enjoy a market share of 35% and 45% respectively and both have grown at a rate of 10% in recent times much higher than industry rates of 7-8%.

This makes it apparent that the company’s profitability is artificially depressed and depends on the whims and fancies of the NPPA. As and when the DPCO (which has 76 drugs under its ambit) is liberalised (around 15 drugs are supposed to be under price control post liberalisation) the profitability of Glaxo would improve substantially.

Market View:
Most analysts have rated Glaxo as a buy for three reasons. Firstly, on account of the parent’s product pipeline post its merger with Smithkline. Second the fact that Glaxo India has not followed minority shareholder unfriendly policies such as setting up a 100% subsidiary or payment of hefty royalties to the parent. And third, the company has substantial cash in its balance sheet that can be used for future acquisition as the Indian pharmaceutical sector witnesses a consolidation.


Equitymaster requests your view! Post a comment on "Glaxo to benefit from likely revision in formulation price". Click here!

  

More Views on News

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 23, 2020 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS